Teva, AbbVie Tell 3rd Circ. New Precedent Won't Help Buyers

By Craig Clough · February 24, 2023, 10:53 PM EST

AbbVie and Teva Pharmaceuticals pushed back Thursday after buyers of the cholesterol drug Niaspan asked the Third Circuit to consider one of its 2022 opinions before deciding whether to deny them...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Case Information

Case Title

In Re: Niaspan Antitrust Litigation

Case Number

Court

Appellate - 3rd Circuit

Nature of Suit

3410 Antitrust

Date Filed

October 14, 2021

Recent Articles By Craig

July 08, 2024
Patient Says Health System Shares Data With Meta, Google
May 31, 2024
9th Circ. Affirms Toss Of Health Center's $8M Cigna Row
May 23, 2024
Charges Tossed For Army Doc, Wife In Russia Data Leak Case
May 23, 2024
LA Jury Awards $58M To Train Yard Worker Injured In Slip
April 30, 2024
Judge Strikes Parts Of NC Law Restricting Abortion Drug
April 29, 2024
9th Circ. Scraps Trans Law Opinion After High Court Ruling
April 10, 2024
DOJ Hits Regeneron With False Claims Act Suit Over Eylea
March 07, 2024
Netflix, Privacy Plaintiffs Scolded For 'Entirely Deficient' Filing
February 14, 2024
Fox News' Sorrento Report Takes Center Stage At 9th Circ.
February 09, 2024
FTC Clears AbbVie To Proceed With $10.1B ImmunoGen Buy